[Therapy of inadequate cerebral circulation].
D000183:Actihaemyl / Q000494:pharmacology; D000925:Anticoagulants / Q000627:therapeutic use; D001537:Bencyclane / Q000494:pharmacology; D001929:Brain Edema / Q000188:drug therapy; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D003907:Dexamethasone / Q000627:therapeutic use; D003911:Dextrans / Q000494:pharmacology; D004876:Ergot Alkaloids / Q000494:pharmacology; D006592:Hexobendine / Q000494:pharmacology; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy; D002504:Meclofenoxate / Q000494:pharmacology; D009540:Nicotinyl Alcohol / Q000494:pharmacology; D010208:Papaverine / Q000494:pharmacology; D011746:Pyrithioxin / Q000494:pharmacology; D013806:Theophylline / Q000031:analogs & derivatives / Q000494:pharmacology; D014971:Xanthinol Niacinate / Q000494:pharmacology; D015016:Yohimbine / Q000494:pharmacology
D000925:Anticoagulants; D003911:Dextrans; D004876:Ergot Alkaloids; D015016:Yohimbine; D000183:Actihaemyl; D001537:Bencyclane; D003907:Dexamethasone; D014971:Xanthinol Niacinate; D009540:Nicotinyl Alcohol; D011746:Pyrithioxin; D006592:Hexobendine; D013806:Theophylline; D002504:Meclofenoxate; D010208:Papaverine
Die Therapie der cerebralen Mangeldurchblutung